Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Pittsburgh, Pennsylvania

This page shows live ClinicalTrials.gov search results for Pittsburgh, Pennsylvania, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
10636
Shown on this page
12
Current sort
Recently updated
Location scope
Pittsburgh, PA
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Pittsburgh, Pennsylvania. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 601–612 of 10,636 matching trials in Pittsburgh, PA.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Pittsburgh

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Active, not recruiting Phase 2 Interventional Results available

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

NCT03778229
View directory record Official record
Conditions
Carcinoma
Interventions
Osimertinib, Savolitinib, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
11
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 15, 2026, 7:40 AM EST
Recruiting Phase 2Phase 3 Interventional

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

NCT03970447
View directory record Official record
Conditions
Glioblastoma
Interventions
Temozolomide, Lomustine, Regorafenib, Radiation, Paxalisib, VAL-083, VT1021, Troriluzole, ADI-PEG 20, AZD1390, Tinostamustine
Drug · Radiation · Biological
Lead sponsor
Global Coalition for Adaptive Research
Other
Eligibility
18 Years and older
Enrollment
2,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
42
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 15, 2026, 7:40 AM EST
Active, not recruiting Not applicable Interventional

Project VIBE: Virtual Intervention for Binge Eating in Adolescents

NCT06819813
View directory record Official record
Conditions
Obesity, Binge-Eating Disorder, Binge Eating
Interventions
Feasibility/Efficacy Testing
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
13 Years to 19 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 15, 2026, 7:40 AM EST
Recruiting Phase 3 Interventional

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

NCT06072781
View directory record Official record
Conditions
Low Grade Serous Ovarian Cancer
Interventions
avutometinib, Defactinib, Pegylated liposomal doxorubicin, Paclitaxel, Letrozole, Anastrozole
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
38
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 15, 2026, 7:40 AM EST
Active, not recruiting Phase 3 Interventional

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

NCT04849728
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
IVA337, Placebo
Drug
Lead sponsor
Inventiva Pharma
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
194
States / cities
Birmingham, Alabama • Dothan, Alabama • Madison, Alabama + 142 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 15, 2026, 7:40 AM EST
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

NCT07645924
View directory record Official record
Conditions
Migraine
Interventions
Elismetrep, Placebo
Drug
Lead sponsor
TriGemX Bio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
113
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 15, 2026, 7:40 AM EST
Active, not recruiting Phase 3 Interventional

Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

NCT06608927
View directory record Official record
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
Quemliclustat, Placebo, Nab-paclitaxel, Gemcitabine
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
49
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 41 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 15, 2026, 7:40 AM EST
Enrolling by invitation No phase listed Observational

A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice

NCT06606340
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Eteplirsen, Golodirsen, Casimersen
Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2033
U.S. locations
23
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 15, 2026, 7:40 AM EST
Recruiting No phase listed Observational

This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

NCT07290803
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
46
States / cities
Birmingham, Alabama • Montgomery, Alabama • Gilbert, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 15, 2026, 7:40 AM EST
Recruiting Phase 2 Interventional

A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant

NCT05675930
View directory record Official record
Conditions
Graft-Versus-Host Disease, GVHD, Undefined
Interventions
Photobiomodulation Therapy, Placebo sham device
Device · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
4 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Bethesda, Maryland • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 15, 2026, 7:40 AM EST
Completed Not applicable Interventional

Haptoglobin Phenotype, Vitamin E and High-density Lipoprotein (HDL) Function in Type 1 Diabetes

NCT01098994
View directory record Official record
Conditions
Type 1 Diabetes, Heart Disease
Interventions
Vitamin E, Dummy pills
Dietary Supplement · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
30 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 15, 2026, 7:40 AM EST
Completed Not applicable Interventional

The Maximizing Extubation Outcomes Through Educational and Organizational Research (METEOR) Trial

NCT05523479
View directory record Official record
Conditions
Acute Respiratory Failure, Airway Extubation
Interventions
Traditional online education, Interprofessional education, Clinical protocol, Risk-stratified preventive post-extubation noninvasive ventilation (NIV) or high-flow nasal cannula oxygen (HFNC), Preventive post-extubation high-flow nasal cannula oxygen (HFNC)
Behavioral · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
12,857 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
17
States / cities
Carlisle, Pennsylvania • Hanover, Pennsylvania • Harrisburg, Pennsylvania + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 15, 2026, 7:40 AM EST